German pharmaceutical company Heidelberg Pharma has filed a lawsuit against Australian drug maker Telix alleging breach of a licence agreement for its kidney cancer diagnostic drug Zircaix.
Treasurer Jim Chalmers has blocked Cosette’s $672 million takeover of Mayne Pharma on national interest grounds after the US drug maker threatened to close a critical drug facility in Adelaide.
The Takeovers Panel has found Cosette cannot close a Mayne Pharma drug manufacturing plant in Adelaide, another win for Mayne in its push to block the US drug maker from walking away from their $672 million merger.
Optus has been hit with a penalty of more than $826,000 after scammers exploited a vulnerability in its third-party verification system and stole $39,000 from customers’ bank accounts.
The Foreign Investment Review Board has extended the deadline for ruling on Cosette’s proposed $672 million takeover of Mayne Pharma.
The Takeovers Panel has agreed to hear Mayne Pharma’s latest dispute with Cosette over the US drug maker’s attempts to walk away from their $672 million merger agreement and extended the timeline for completing the deal.
A judge has approved a “modest” $8.7 million settlement in a class action against medical device maker Exactech over allegedly defective joint replacements, saying the settlement was fair and reasonable given the limited assets of the company, whose parent has filed for bankruptcy in the US.
Mayne Pharma has secured an extension of the deadline for securing Foreign Investment Review Board approval of its $672 million tie-up with US drug maker Cosette.
Cosette plans to appeal a ruling that rejected its bid to terminate an agreement to merge with Mayne Pharma, as the US drug company also refuses to agree to conditions needed to win Foreign Investment Review Board approval for the tie-up.
Mayne Pharma is not walking away from US drug maker Cosette’s proposed takeover without a fight, filing an application with the Takeovers Panel to force Cosette to agree to the conditions needed to win FIRB approval for the $672 million deal.